Sutro Biopharma
Stock Forecast, Prediction & Price Target
Sutro Biopharma Financial Estimates
Sutro Biopharma Revenue Estimates
Sutro Biopharma EBITDA Estimates
Sutro Biopharma Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $61.88M N/A | $67.77M 9.52% | $153.73M 126.83% | Avg: $62.17M Low: $16.76M High: $182.76M avg. -59.55% | Avg: $81.65M Low: $29.61M High: $207.36M avg. 31.33% | Avg: $147.10M Low: $53.36M High: $373.59M avg. 80.16% | Avg: $319.24M Low: $115.80M High: $810.73M avg. 117.00% |
Net Income
% change YoY
| $-108.67M N/A | $-119.20M -9.68% | $-106.79M 10.41% | Avg: $-270.76M Low: $-292.39M High: $-44.52M avg. -153.54% | Avg: $-269.37M Low: $-285.77M High: $-58.35M avg. 0.51% | Avg: $-143.86M Low: $-431.80M High: $-24.68M avg. 46.59% | Avg: $-65.73M Low: $-197.29M High: $-11.27M avg. 54.30% |
EBITDA
% change YoY
| $-93.10M N/A | $-125.48M -34.78% | $-67.91M 45.87% | Avg: $-56.40M Low: $-165.81M High: $-15.20M avg. 16.94% | Avg: $-74.08M Low: $-188.13M High: $-26.87M avg. -31.33% | Avg: $-133.46M Low: $-338.95M High: $-48.41M avg. -80.16% | Avg: $-289.64M Low: $-735.56M High: $-105.06M avg. -117.00% |
EPS
% change YoY
| -$2.36 N/A | -$2.35 0.42% | -$1.78 24.25% | Avg: -$3.24 Low: -$4.86 High: -$0.74 avg. -81.93% | Avg: -$2.99 Low: -$4.75 High: -$0.97 avg. 7.55% | Avg: -$2.39 Low: -$7.18 High: -$0.41 avg. 20.12% | Avg: -$1.09 Low: -$3.28 High: -$0.19 avg. 54.30% |
Operating Expenses
% change YoY
| $160.40M N/A | $196.71M 22.63% | $243.00M 23.53% | Avg: $46.88M Low: $12.64M High: $137.83M avg. -80.70% | Avg: $61.58M Low: $22.33M High: $156.38M avg. 31.33% | Avg: $110.94M Low: $40.24M High: $281.75M avg. 80.16% | Avg: $240.76M Low: $87.33M High: $611.42M avg. 117.00% |
FAQ
What is Sutro Biopharma stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -13.03% in 2025-2028.
We have gathered data from 10 analysts. Their low estimate is -292.39M, average is -270.76M and high is -44.52M.
What is Sutro Biopharma stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 42.23% in 2025-2028.
We have gathered data from 8 analysts. Their low revenue estimate is $16.76M, average is $62.17M and high is $182.76M.
What is Sutro Biopharma stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 0.01% in 2025-2028.
We have gathered data from 10 analysts. Their low earnings per share estimate is -$4.86, average is -$3.24 and high is $-0.74.
What is the best performing analyst?
In the last twelve months analysts have been covering Sutro Biopharma stock. The most successful analyst is Tazeen Ahmad.